Rocket Pharmaceuticals, Inc. (RCKT)
NASDAQ: RCKT · IEX Real-Time Price · USD
21.98
-0.12 (-0.54%)
Apr 26, 2024, 4:00 PM EDT - Market closed
Rocket Pharmaceuticals Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
268
Market Cap
1.99B USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 0 | - | - |
Dec 31, 2022 | 0 | - | - |
Dec 31, 2021 | 0 | - | - |
Dec 31, 2020 | 0 | - | - |
Dec 31, 2019 | 0 | - | - |
Dec 31, 2018 | 0 | - | - |
Dec 31, 2017 | 0 | - | - |
Dec 31, 2016 | 0 | - | - |
Dec 31, 2015 | 0 | - | - |
Dec 31, 2014 | 0 | - | - |
Dec 31, 2013 | 0 | - | - |
Dec 31, 2012 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Owens & Minor | 10.33B |
CONMED | 1.26B |
Amphastar Pharmaceuticals | 644.40M |
RxSight | 89.08M |
Kymera Therapeutics | 78.59M |
Intellia Therapeutics | 36.28M |
NewAmsterdam Pharma Company | 15.66M |
Avidity Biosciences | 9.56M |
RCKT News
- 24 days ago - Rocket Pharmaceuticals Announces European Medicines Agency Acceptance of RP-L102 Marketing Authorization Application for the Treatment of Fanconi Anemia - Business Wire
- 4 weeks ago - Rocket Pharmaceuticals Announces Appointment of Aaron Ondrey as Chief Financial Officer and Additional Updates to Corporate Leadership Team - Business Wire
- 2 months ago - Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Progress - Business Wire
- 2 months ago - Rocket Pharmaceuticals Announces Update on FDA Review Timeline of KRESLADI™ (marnetegragene autotemcel) for the Treatment of Severe Leukocyte Adhesion Deficiency-I (LAD-I) - Business Wire
- 4 months ago - Rocket Pharmaceuticals to Present at 42nd Annual J.P. Morgan Healthcare Conference - Business Wire
- 4 months ago - Best Small-Cap Stocks to Buy for 2024 and Beyond - Kiplinger
- 4 months ago - Rocket Pharmaceuticals Appoints R. Keith Woods to Board of Directors - Business Wire
- 6 months ago - Rocket Pharmaceuticals Reports Third Quarter 2023 Financial Results and Highlights Recent Progress - Business Wire